11 completed, 6 active not recruiting, 1 recruiting, 1 withdrawn. 10 Phase 1, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 7, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 10 | Active not recruiting 5, Completed 4, Recruiting 1 |
Follow Refractory Primary Central Nervous System Neoplasm: new trials by email Literature Review of Refractory Primary Central Nervous System Neoplasm trials Research Report on Refractory Primary Central Nervous System Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors LUTATHERA® (Lutetium Lu 177 dotatate) - High Grade Glioma, Meningioma | Phase 1 / Phase 2 | Recruiting | Nationwide Children's Hospital | 65 | 2022-11-21 | 2026-07-20 |
| Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study Biospecimen Collection, Ipilimumab, Nivolumab - Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2021-05-11 | 2026-06-10 | |
| Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors Biospecimen Collection, Magnetic Resonance Imaging, Savolitinib - Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 41 | 2018-11-27 | 2026-07-30 |
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-06-05 | 2026-10-16 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2018-04-17 | 2026-10-28 |
| Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma Irinotecan, Pevonedistat, Temozolomide - Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm | Phase 1 | Completed | Children's Oncology Group | 30 | 2018-01-11 | 2024-10-22 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2017-11-28 | 2026-04-21 |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Vemurafenib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 4 | 2017-11-08 | 2025-01-27 |
| Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2017-10-30 | 2025-02-05 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 9 | 2017-08-23 | 2026-06-17 |
| Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm | Phase 1 | Completed | Children's Oncology Group | 33 | 2017-08-15 | 2025-01-14 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Cabozantinib, Cabozantinib S-malate, Pharmacological Study - Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 109 | 2017-05-18 | 2026-08-28 |
| Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Laboratory Biomarker Analysis, Pharmacokinetic (PK) study, Prexasertib - Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm | Phase 1 | Completed | Children's Oncology Group | 30 | 2017-02-27 | 2023-12-20 |
| Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Entinostat, Laboratory Biomarker Analysis, Pharmacological Study - Brain Stem Neoplasm, Pineal Region Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 21 | 2017-01-06 | 2023-10-17 |
| Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas Pharmacological Study, Selinexor - Malignant Glioma, Recurrent Brain Neoplasm | Phase 1 | Completed | Children's Oncology Group | 59 | 2015-10-30 | 2025-01-14 |
| Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors Laboratory Biomarker Analysis, Pharmacological Study, Pomalidomide - Neurofibromatosis Type 1, Recurrent Childhood Brain Stem Glioma | Phase 1 | Completed | National Cancer Institute (NCI) | 29 | 2015-07-14 | 2022-04-25 |
| Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Malignant Solid Neoplasm, Recurrent Melanoma | Phase 1 | Completed | National Cancer Institute (NCI) | 41 | 2012-11-14 | 2023-12-22 |
Central Nervous System Neoplasms (19) · Glioma (10) · Neuroblastoma (9) · Ependymoma (8) · Hepatoblastoma (8) · Lymphoma, Non-Hodgkin (8) · Medulloblastoma (8) · Wilms Tumor (8) · Histiocytosis, Langerhans-Cell (7) · Neuroectodermal Tumors, Primitive, Peripheral (7) · Osteosarcoma (7) · Rhabdoid Tumor (7) · Rhabdomyosarcoma (7) · Sarcoma (7) · Lymphoma (4)
Neoplasms (19) · Neoplasms by Site (19) · Nervous System Diseases (19) · Nervous System Neoplasms (19) · Neoplasms by Histologic Type (17) · Neoplasms, Glandular and Epithelial (16) · Neoplasms, Nerve Tissue (16) · Neuroectodermal Tumors (16) · Neoplasms, Germ Cell and Embryonal (15) · Neoplasms, Neuroepithelial (14) · Hemic and Lymphatic Diseases (12) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Lymphatic Diseases (12) · Lymphoproliferative Disorders (12)
Specimen Handling (7) · Magnetic Resonance Spectroscopy (6) · Phantoms, Imaging (6) · X-Rays (6) · Biopsy (4) · Nuclear Medicine Department, Hospital (4) · Irinotecan (2) · LY3023414 (2) · Temozolomide (2) · Vemurafenib (2) · cabozantinib (2) · ensartinib (2) · erdafitinib (2) · larotrectinib (2) · olaparib (2)
National Cancer Institute (NCI) (14) · Children's Oncology Group (4) · Nationwide Children's Hospital (1)
United States (19) · Puerto Rico (8) · Canada (5) · Australia (2)
Julia Glade-Bender (2) · AeRang Kim (1) · Alice Lee (1) · Andrew Bukowinski (1) · Carl E Allen (1) · Cynthia J Wetmore (1) · Daniel A Morgenstern (1) · Donald W Parsons (1) · Jason R Fangusaro (1) · Jennifer H Foster (1) · Katherine A Janeway (1) · Margot Lazow, MD (1) · Meredith K Chuk (1) · Meredith S Irwin (1) · Ralph Salloum (1)
PMID 31401903, PMID 33591402, PMID 33881209, PMID 34486544, PMID 35353553, PMID 35363510, PMID 38815151, PMID 38873934, PMID 39487711, PMID 39998852, PMID 41166674, PMID 42686334
U10CA180886 (9), UM1CA097452 (6), UM1CA081457 (3), P30CA015704 (1), UM1CA154967 (1)